| |
Start and End Date |
Company/Institution
Investigator |
Disease |
Amount |
Time Period |
Title |
 |
12/29/2011 -10/15/2012 |
Tivorsan Pharmaceuticals, Joel Braunstein, MD |
Duchenne muscular dystrophy |
$1,000,000 |
1 year |
Recombinant Biglycan for the Treatment of Duchenne Muscular Dystrophy |
 |
12/15/2011-7/26/2012 |
Summit Plc, Jon Tinsley, PhD |
Duchenne muscular dystrophy |
$750,000 |
1 year |
SMT C1100 Utrophin Upregulator: Request for Phase I Clinical Trial Funding |
 |
12/1/2011 – 1/15/2013 |
ALSTDI, Steve Perrin, PhD |
Amyotrophic Lateral Sclerosis |
$278,850 |
1 year |
Ctla4_Fc: Immunomodulation of Costimulatory Signaling as a Therapeutic Strategy for ALS |
 |
4/1/2011 – 3/31/2014 |
Wake Forest University,
Martin Childers, Ph.D. |
X-linked myotubular myopathy |
$369,365 |
3 years |
Gene therapy in canine myotubular myopathy |
 |
3/11/2011 – 3/15/2012 |
ALS Biopharma,
Allen Reitz |
Amyotrophic lateral sclerosis |
$250,000 |
1 year |
Development of Heat Shock Protein 70-Based Therapy for Amyotrophic Lateral Sclerosis |
 |
3/3/2011 – 12/1/2013 |
University of Illinois, Matthew Meriggioli |
Myasthenia gravis |
$530,480 |
3 years |
GM-CSF in the Therapy of Autoimmune Myasthenia Gravis |
Glialogix,
Inc. |
2/15/2011 – 11/15/2011 |
Glialogix, Mark Moore |
Amyotrophic lateral sclerosis |
$268,000 |
1 year |
Investigation of GLX1112, a Potential Pharmacological Agent for the Treatment of Amyotrophic Lateral Sclerosis, Using the SOD1G93A Mouse, a Standard Transgenic Mouse Model of ALS |
|
1/1/2011 - 12/31/2011 |
ALS-TDI,
Steve Perrin, Ph.D. |
Amyotrophic lateral sclerosis
Through Augie’s Quest Initiative |
$2.0 million |
1 year |
Development of Therapeutic Interventions for Amyotrophic Lateral Sclerosis |
 |
12/22/2010 – 11/28/11 canceled due to milestone failure (4/28/2011) |
Acceleron Pharma,
Chris Rovaldi |
Duchenne muscular dystrophy |
$1.5 million |
3 years |
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy |
 |
12/1/2010 - 6/30/2012 |
Repligen Corp.,
James Rusche, Ph.D. |
Spinal muscular atrophy |
$1,423,247 |
2 years |
Development of a DcpS Inhibitor for SMA |
 |
8/1/2010 – 9/30/2013 |
University of California, Los Angeles,
Carmen Bertoni, Ph.D. |
Duchenne muscular dystrophy |
$476,465 |
3 years |
Preclinical Investigation of RTC#13 for the Treatment of DMD |
| |
4/1/2010 - 3/31/2012 |
4s3 Biosciences,
Dustin Armstrong, Ph.D. |
Myotubular myopathy |
$260,291 |
2 years |
Muscle Targeted Myotubularin 1 for Treatment of Congenital Myotubular Myopathy |
 |
2/10/2010 - 6/30/2012 |
Nationwide Children’s Hospital,
Jerry Mendell, M.D. |
Limb-girdle muscular dystrophy |
$458,814 |
2 years |
Limb Strength by Vascular Delivery of the Alpha-Sarcoglycan Gene in LGMD2D |
 |
1/12/2010 – 11/28/11 canceled due to milestone failure (3/31/10) |
PTC Therapeutics, Langdon Miller, M.D. |
Duchenne muscular dystrophy |
$1.0 million |
1 year |
Phase 2a Trial of Ataluren in Nonambulatory Boys with Nonsense Mutation DMD/BMD |
 |
1/12/2010 - 12/1/2010 |
ReveraGen BioPharma, Inc.,
Erica Reeves, Ph.D. |
Duchenne muscular dystrophy |
$360,000 |
1 year |
Preclinical Validation of a Nonhormonal Steroid for Duchenne Muscular Dystrophy |
|
1/1/2010 - 12/31/2010 |
ALS-TDI,
Steve Perrin, Ph.D. |
Amyotrophic lateral sclerosis
Through Augie’s Quest Initiative |
$2.5 million |
1 year |
Development of Therapeutic Interventions for Amyotrophic Lateral Sclerosis |
 |
12/15/2010 - 9/30/2010 |
Catabasis
Pharmaceuticals,
Michael Jirousek, Ph.D. |
Duchenne muscular dystrophy |
$150,000 |
1 year |
Preclinical Validation of a Small Molecular Anti-inflammatory Compound for Duchenne Muscular Dystrophy |
|
11/1/2009 - 6/20/2010 |
Repligen Corp.,
James Rusche, Ph.D. |
Friedreich’s ataxia |
$731,534 |
1 year |
Clinical Development of a HDAC Inhibitor for Friedreich’s Ataxia |
